Evidence map›Paper›PMID 40195449›Full record

ArticleNature medicine2025

Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.

Raffaella Molteni, Martina Fiumara, Corrado Campochiaro, Roberta Alfieri, Guido Pacini, Eugenia Licari, Alessandro Tomelleri, Elisa Diral, Angelica Varesi, Alessandra Weber and 27 more

Registry-linked trialAbstract read
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07746986 (Devising Targeted Therapies Against VEXAS Syndrome by Untangling the Vicious Interplay of Inflammation and Clonal Dominance), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07746986 completednot on this map

Devising Targeted Therapies Against VEXAS Syndrome by Untangling the Vicious Interplay of Inflammation and Clonal Dominance

TypeobservationalSponsorIRCCS San RaffaeleRan2021 to 2026Enrolled60ConditionsVEXAS
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Myelodysplasia in VEXAS syndrome.Blood advances · 2026
    Review
  3. Review
  4. Genetic influences on haematopoiesis.Nature reviews. Genetics · 2026
    Review
  5. Review
  6. Cell autonomous inflammation in VEXAS is mediated by cGAS-STING.bioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. VEXAS syndrome.Nature reviews. Disease primers · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Raffaella Molteni *Vita-Salute San Raffaele University, Milan, Italy. molteni.raffaella@hsr.it.ORCID http://orcid.org/0000-0001-6605-2346
Martina Fiumara *Vita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0009-0007-5934-9273
Corrado CampochiaroVita-Salute San Raffaele University, Milan, Italy.
Roberta AlfieriNational Research Council, Institute for Biomedical Technologies, Segrate, Italy.ORCID http://orcid.org/0000-0001-6922-9696
Guido PaciniSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eugenia LicariSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alessandro TomelleriVita-Salute San Raffaele University, Milan, Italy.
Elisa DiralUnit of Hematology and Stem Cell Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Angelica VaresiSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alessandra WeberVita-Salute San Raffaele University, Milan, Italy.
Pamela QuarantaSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Luisa AlbanoSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-0013-4741
Chiara GaddoniSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Luca Basso-RicciSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Davide StefanoniDivision of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Laura AlessandriniVita-Salute San Raffaele University, Milan, Italy.
Sara Degl'InnocentiSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesca SanvitoSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-4046-8420
Gregorio Maria BergonziVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0009-0007-1339-2663
Andrea AnnoniSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-8541-2578
Maddalena PanigadaDivision of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eleonora CantoniDivision of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Daniele CanaruttoVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0001-6999-8479
Stephanie Z XiePrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-0284-494X
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Denver, CO, USA.ORCID http://orcid.org/0000-0002-2258-6490
Raffaella Di MiccoSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-0639-8238
Alessandro AiutiVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0002-5398-1717
Fabio CiceriVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0003-0873-0123
Giacomo De LucaVita-Salute San Raffaele University, Milan, Italy.
Lorenzo DagnaVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0002-7428-315X
Marco Matucci-CerinicVita-Salute San Raffaele University, Milan, Italy.
Ivan MerelliSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Simone CenciVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0003-1215-7518
Serena ScalaSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giulio CavalliUnit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Luigi NaldiniVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0002-7835-527X
Samuele FerrariVita-Salute San Raffaele University, Milan, Italy. ferrari.samuele@hsr.it.ORCID http://orcid.org/0000-0003-1122-1231

Funding

American Society of Hematology (ASH) 2024 ASH Global Research AwardElse Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation) PrizeFondazione Telethon (Telethon Foundation) SR-Tiget Core GrantMinistero della Salute (Ministry of Health, Italy) GR-2019-12369499Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2022APWTE3
6 · The paper itself

Abstract

Clonal dominance characterizes hematopoiesis during aging and increases susceptibility to blood cancers and common nonmalignant disorders. VEXAS syndrome is a recently discovered, adult-onset, autoinflammatory disease burdened by a high mortality rate and caused by dominant hematopoietic clones bearing somatic mutations in the UBA1 gene. However, pathogenic mechanisms driving clonal dominance are unknown. Moreover, the lack of disease models hampers the development of disease-modifying therapies. In the present study, we performed immunophenotype characterization of hematopoiesis and single-cell transcriptomics in a cohort of nine male patients with VEXAS syndrome, revealing pervasive inflammation across all lineages. Hematopoietic stem and progenitor cells (HSPCs) in patients are skewed toward myelopoiesis and acquire senescence-like programs. Humanized models of VEXAS syndrome, generated by inserting the causative mutation in healthy HSPCs through base editing, recapitulated proteostatic defects, cytological alterations and senescence signatures of patients' cells, as well as hematological and inflammatory disease hallmarks. Competitive transplantations of human UBA1-mutant and wild-type HSPCs showed that, although mutant cells are more resilient to the inflammatory milieu, probably through the acquisition of the senescence-like state, wild-type ones are progressively exhausted and overwhelmed by VEXAS clones, overall impairing functional hematopoiesis and leading to bone marrow failure. Our study unveils the mechanism of clonal dominance and provides models for preclinical studies and preliminary insights that could inform therapeutic strategies.

Indexed as

Clonal HematopoiesisHematopoiesisHematopoietic Stem CellsUbiquitin-Activating EnzymesAdultAnimalsCellular SenescenceHumansInflammationMaleMutationMyelodysplastic SyndromesSkin Diseases, GeneticSyndromeUBA1 protein, humanUbiquitin-Activating Enzymes

Identifiers

PMID40195449
PMCPMC12176642

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.